WO2001023550A3 - Pca3 messenger rna species in benign and malignant prostate tissues - Google Patents

Pca3 messenger rna species in benign and malignant prostate tissues Download PDF

Info

Publication number
WO2001023550A3
WO2001023550A3 PCT/CA2000/001154 CA0001154W WO0123550A3 WO 2001023550 A3 WO2001023550 A3 WO 2001023550A3 CA 0001154 W CA0001154 W CA 0001154W WO 0123550 A3 WO0123550 A3 WO 0123550A3
Authority
WO
WIPO (PCT)
Prior art keywords
pca3
benign
rna
messenger rna
rna species
Prior art date
Application number
PCT/CA2000/001154
Other languages
French (fr)
Other versions
WO2001023550A2 (en
Inventor
Ursula Busse
Camille Chypre
Yves Fradet
Original Assignee
Diagnocure Inc
Ursula Busse
Camille Chypre
Yves Fradet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnocure Inc, Ursula Busse, Camille Chypre, Yves Fradet filed Critical Diagnocure Inc
Priority to EP00965690A priority Critical patent/EP1222266B1/en
Priority to CA002385477A priority patent/CA2385477C/en
Priority to AU76364/00A priority patent/AU7636400A/en
Priority to DE60027027T priority patent/DE60027027T2/en
Priority to JP2001526932A priority patent/JP2003510075A/en
Publication of WO2001023550A2 publication Critical patent/WO2001023550A2/en
Publication of WO2001023550A3 publication Critical patent/WO2001023550A3/en
Priority to CY20061100782T priority patent/CY1105048T1/en
Priority to US12/635,917 priority patent/US7927806B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer.
PCT/CA2000/001154 1999-09-29 2000-09-29 Pca3 messenger rna species in benign and malignant prostate tissues WO2001023550A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP00965690A EP1222266B1 (en) 1999-09-29 2000-09-29 Pca3 messenger rna in benign and malignant prostate tissues
CA002385477A CA2385477C (en) 1999-09-29 2000-09-29 Pca3 messenger rna species in benign and malignant prostate tissues
AU76364/00A AU7636400A (en) 1999-09-29 2000-09-29 Pca3 messenger rna species in benign and malignant prostate tissues
DE60027027T DE60027027T2 (en) 1999-09-29 2000-09-29 PCA3 MRNA IN GOOD AND MASTILE PROSTATE WEAVE
JP2001526932A JP2003510075A (en) 1999-09-29 2000-09-29 PCA3 messenger RNA species in benign and malignant prostate tissue
CY20061100782T CY1105048T1 (en) 1999-09-29 2006-06-09 PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES
US12/635,917 US7927806B2 (en) 1999-09-29 2009-12-11 Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15659499P 1999-09-29 1999-09-29
US60/156,594 1999-09-29

Publications (2)

Publication Number Publication Date
WO2001023550A2 WO2001023550A2 (en) 2001-04-05
WO2001023550A3 true WO2001023550A3 (en) 2001-08-16

Family

ID=22560223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001154 WO2001023550A2 (en) 1999-09-29 2000-09-29 Pca3 messenger rna species in benign and malignant prostate tissues

Country Status (12)

Country Link
US (8) US7368545B1 (en)
EP (1) EP1222266B1 (en)
JP (3) JP2003510075A (en)
AT (1) ATE321857T1 (en)
AU (1) AU7636400A (en)
CA (1) CA2385477C (en)
CY (1) CY1105048T1 (en)
DE (1) DE60027027T2 (en)
DK (1) DK1222266T3 (en)
ES (1) ES2260059T3 (en)
PT (1) PT1222266E (en)
WO (1) WO2001023550A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045420A1 (en) 1997-04-10 1998-10-15 Diagnocure Inc. Pca3, pca3 genes, and methods of use
PT1222266E (en) 1999-09-29 2006-07-31 Diagnocure Inc PCA3 MESSENGER RNA IN BENEFICIAL AND MALIGNAL PROSTATE TISSUES
DE10230692A1 (en) * 2002-07-08 2004-02-12 Epigenomics Ag Methods and nucleic acids for the analysis of methylation patterns within the DD3 gene
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
CA2432365A1 (en) * 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
CA2491067A1 (en) * 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
JP5808349B2 (en) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー Biomarkers for theranosis
BR112012025593A2 (en) 2010-04-06 2019-06-25 Caris Life Sciences Luxembourg Holdings circulating biomarkers for disease
EP3112466A1 (en) 2015-07-01 2017-01-04 Samsung Electronics Co., Ltd. Composition for reducing cellular senescence level including activity inhibitor inhibiting dcun1d3 activity or expression inhibitor inhibiting expression of dcun1d3-encoding gene and use thereof
CN110951871B (en) * 2019-11-21 2024-01-05 瑞博奥(广州)生物科技股份有限公司 PCA3 and PSA RNA detection kit and amplification system

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045420A1 (en) * 1997-04-10 1998-10-15 Diagnocure Inc. Pca3, pca3 genes, and methods of use

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US514925A (en) * 1894-02-20 Leaume
FR2422956A1 (en) * 1978-04-13 1979-11-09 Pasteur Institut METHOD OF DETECTION AND CHARACTERIZATION OF A NUCLEIC ACID OR OF A SEQUENCE OF THE SAME, AND ENZYMATIC REAGENT FOR THE IMPLEMENTATION OF THIS PROCESS
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4690890A (en) 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
US4786600A (en) * 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
JPS6147500A (en) 1984-08-15 1986-03-07 Res Dev Corp Of Japan Chimera monoclonal antibody and its preparation
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (en) 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
AU606320B2 (en) 1985-11-01 1991-02-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4800159A (en) * 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4851331A (en) * 1986-05-16 1989-07-25 Allied Corporation Method and kit for polynucleotide assay including primer-dependant DNA polymerase
FR2602592B1 (en) 1986-08-06 1989-06-30 Alain Baret USE OF THE ENZYMATIC XANTHINE-OXYDASE SYSTEM IN IMMUNOALYSIS, CORRESPONDING ASSAY PROCESSES AND REAGENT PACKAGES NECESSARY FOR THE IMPLEMENTATION OF THESE PROCESSES.
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5202231A (en) * 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5149625A (en) * 1987-08-11 1992-09-22 President And Fellows Of Harvard College Multiplex analysis of DNA
US5639604A (en) * 1987-09-21 1997-06-17 Gen-Probe Incorporated Homogeneous protection assay
US5585481A (en) * 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5283174A (en) * 1987-09-21 1994-02-01 Gen-Probe, Incorporated Homogenous protection assay
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
US5002867A (en) * 1988-04-25 1991-03-26 Macevicz Stephen C Nucleic acid sequence determination by multiple mixed oligonucleotide probes
NL8801147A (en) * 1988-05-02 1989-12-01 Tno METHOD FOR DETECTING GENETIC VARIATION, AND SUITABLE KIT.
DK167254B1 (en) 1988-07-21 1993-09-27 Hartmann As Brdr PROCEDURE FOR THE PREPARATION OF FORMED ARTICLES OF A FLUIDIZED CELLULOSE FIBER MATERIAL
US5183949A (en) 1988-09-22 1993-02-02 The United States Of America As Represented By The Department Of Health And Human Services Rabbit model for diagnosing and testing vaccines or therapeutic agents against aids
US5118801A (en) * 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5219989A (en) * 1988-12-13 1993-06-15 Mcgill University Bifunctional protein for the isolation of capped mRNA
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5175383A (en) * 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
US5112736A (en) * 1989-06-14 1992-05-12 University Of Utah Dna sequencing using fluorescence background electroblotting membrane
US5656207A (en) * 1989-06-24 1997-08-12 Gen Probe Incorporated Detecting or quantifying multiple analytes using labelling techniques
US5174986A (en) * 1989-07-05 1992-12-29 Genpharm International, Inc. Method for determining oncogenic potential of a chemical compound
CA2020958C (en) * 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
AU662906B2 (en) 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
CA2082411A1 (en) * 1991-06-28 1992-12-29 Robert D. Rosenberg Localized oligonucleotide therapy
DE4209215A1 (en) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh HCV PEPTIDE ANTIGEN AND METHOD FOR DETERMINING HCV
AU2468992A (en) 1991-08-16 1993-03-16 General Hospital Corporation, The Method of gene delivery to post-mitotic cells
AU3129993A (en) 1991-11-08 1993-06-07 Massachusetts Institute Of Technology Localized oligonucleotide therapy
EP0618972A1 (en) * 1991-12-16 1994-10-12 E.I. Du Pont De Nemours And Company CONSTITUTIVE EXPRESSION OF P450SOY AND FERREDOXIN-SOY IN $i(STREPTOMYCES), AND BIOTRANSFORMATION OF CHEMICALS BY RECOMBINANT ORGANISMS
ATE515510T1 (en) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc OLIGONUCLEOTIDES MODIFIED BY DNA SECTIONS
CA2135073C (en) * 1992-05-06 2002-11-19 Daniel L. Kacian Nucleic acid sequence amplification method, composition and kit
US5674682A (en) * 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
EP1757694A3 (en) 1992-11-05 2008-02-27 Sloan Kettering Institute For Cancer Research Prostate-specific membrane antigen
US5503980A (en) * 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5773705A (en) * 1992-12-31 1998-06-30 Wisconsin Alumni Research Foundation Ubiquitin fusion protein system for protein production in plants
KR100316205B1 (en) 1993-01-07 2002-04-24 아브람 엠. 골드핑거 Antisense Inhibition of c-myc to Regulate Smooth Muscle Cell Proliferation
US5422252A (en) * 1993-06-04 1995-06-06 Becton, Dickinson And Company Simultaneous amplification of multiple targets
US5861242A (en) * 1993-06-25 1999-01-19 Affymetrix, Inc. Array of nucleic acid probes on biological chips for diagnosis of HIV and methods of using the same
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US5925517A (en) * 1993-11-12 1999-07-20 The Public Health Research Institute Of The City Of New York, Inc. Detectably labeled dual conformation oligonucleotide probes, assays and kits
AU687535B2 (en) * 1994-03-16 1998-02-26 Gen-Probe Incorporated Isothermal strand displacement nucleic acid amplification
WO1995028498A1 (en) 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
AU3889595A (en) 1994-10-05 1996-05-02 Amgen, Inc. Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein
EP0709466B1 (en) * 1994-10-28 2006-09-27 Gen-Probe Incorporated Compositions and methods for the simultaneous detection and quantification of multiple specific nucleic acid sequences
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
DE19513152A1 (en) * 1995-04-07 1996-10-10 Bundesrep Deutschland Use of an "immunodeficiency virus suppressing lymphokine (ISL)" to inhibit virus multiplication, in particular of retroviruses
US5609989A (en) * 1995-06-06 1997-03-11 International Business Machines, Corporation Acid scavengers for use in chemically amplified photoresists
US5731148A (en) 1995-06-07 1998-03-24 Gen-Probe Incorporated Adduct protection assay
DE69736667T2 (en) 1996-07-16 2007-09-06 Gen-Probe Inc., San Diego PROCESS FOR THE DETECTION AND AMPLIFICATION OF NUCLEIC ACID SEQUENCES USING MODIFIED OLIGONUCLEOTIDES WITH INCREASED TARGET MELT TEMPERATURE (TM)
US6479263B1 (en) * 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
US6261562B1 (en) 1997-02-25 2001-07-17 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
NZ337446A (en) 1997-02-25 2001-02-23 Corixa Corp Immunogenic portions of a prostate protein and their use in immunotherapy of prostate cancer and methods for their use
US6465611B1 (en) * 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6395278B1 (en) * 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
WO1998050583A1 (en) * 1997-05-02 1998-11-12 Gen-Probe Incorporated Two-step hybridization and capture of a polynucleotide
US6534273B2 (en) * 1997-05-02 2003-03-18 Gen-Probe Incorporated Two-step hybridization and capture of a polynucleotide
US6251638B1 (en) * 1997-05-30 2001-06-26 Diagen Corporation Methods for detection of nucleic acid sequences in urine
US20020035244A1 (en) 1997-09-09 2002-03-21 Maurice Cohen Reagents and methods useful for detecting diseases of the prostate
KR20070112860A (en) 1998-07-14 2007-11-27 코릭사 코포레이션 An isolated immnogenic portion of the prostate tumor protein and methods for diagnosis of prostate cancer using the same
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
JP4495349B2 (en) * 1999-01-28 2010-07-07 ジェン−プローブ・インコーポレーテッド Nucleic acid sequences for detecting cancer genetic markers in biological samples
FI990382A0 (en) 1999-02-23 1999-02-23 Arctic Partners Oy Ab New diagnostic method
US6528260B1 (en) * 1999-03-25 2003-03-04 Genset, S.A. Biallelic markers related to genes involved in drug metabolism
WO2000058470A1 (en) 1999-03-26 2000-10-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, pcgem1, and methods of using pcgem1 to detect, treat, and prevent prostate cancer
PT1222266E (en) 1999-09-29 2006-07-31 Diagnocure Inc PCA3 MESSENGER RNA IN BENEFICIAL AND MALIGNAL PROSTATE TISSUES
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
AU1656501A (en) 1999-11-12 2001-06-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
ES2303736T3 (en) 1999-12-17 2008-08-16 Bio Merieux PROCEDURE TO MARK A NUCLEIC ACID.
MXPA02006934A (en) 2000-01-14 2003-01-28 Corixa Corp Compositions and methods for the therapy and diagnosis of prostate cancer.
US20020168638A1 (en) * 2000-01-24 2002-11-14 Robert Schlegel Compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
WO2001060860A2 (en) 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
AU2001249549A1 (en) 2000-03-27 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
FR2810114B1 (en) 2000-06-13 2002-08-23 Bio Merieux METHOD, METHOD, IMMUNOLOGICAL TEST AND DIAGNOSTIC KIT FOR PROSTATE ADENOCARCINOMA OR BENIGN PROSTATE HYPERTROPHY
US20030031678A1 (en) 2000-09-19 2003-02-13 Shujath Ali Compositions and methods relating to prostate specific genes and proteins
MXPA03003151A (en) 2000-10-13 2003-08-19 Eos Biotechnology Inc Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
US6897024B2 (en) * 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US20050282170A1 (en) 2003-02-07 2005-12-22 Diagnocure Inc. Method to detect prostate cancer in a sample
CA2432365A1 (en) * 2003-06-30 2004-12-30 Jack A. Schalken Specific method of prostate cancer detection based on pca3, and kits therefore
CA2491067A1 (en) * 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045420A1 (en) * 1997-04-10 1998-10-15 Diagnocure Inc. Pca3, pca3 genes, and methods of use

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BUSSEMAKERS M ET AL: "Assessment of the clinical usefulness of the prostate-cancer-specific DD3 gene.", EUROPEAN UROLOGY, vol. 36, no. 5, November 1999 (1999-11-01), 3rd World Congress on Urological Research;Paris, France; September 30-October 3, 1999, pages 508, XP000990348, ISSN: 0302-2838 *
BUSSEMAKERS M J G ET AL: "A NEW PROSTATE SPECIFIC MARKER, OVEREXPRESSED IN PROSTATIC TUMORS", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH,US,PHILADELPHIA, AACR, vol. MEETING 87, 1 March 1996 (1996-03-01), pages 515, XP002074304, ISSN: 0197-016X *
BUSSEMAKERS M J G ET AL: "A NEW PROSTATE-SPECIFIC MARKER, STRONGLY OVEREXPRESSED IN PROSTATIC TUMORS", UROLOGICAL RESEARCH,DE,SPRINGER VERLAG, BERLIN, vol. 25, no. 1, 1 February 1997 (1997-02-01), pages 76, XP002074305, ISSN: 0300-5623 *
BUSSEMAKERS MARION J G: "Changes in gene expression and targets for therapy.", EUROPEAN UROLOGY, vol. 35, no. 5-6, May 1999 (1999-05-01), pages 408 - 412, XP000990349, ISSN: 0302-2838 *
DATABASE EMBL 2 November 1999 (1999-11-02), M.J. BUSSEMAKERS ET AL: "Homo sapiens non-coding RNA DD3 gene, exons 2, 3, and 4", XP002162960 *
M.J. BUSSEMAKERS ET AL: "DD3: a new prostate-specific gene, highly overexpressed in prostate cancer", CANCER RESEARCH, vol. 59, 1 December 1999 (1999-12-01), US, American Association for Cancer Research , Baltimore, MD, pages 5975 - 5979, XP002923011 *

Also Published As

Publication number Publication date
DK1222266T3 (en) 2006-07-10
US20180171416A1 (en) 2018-06-21
US8241848B2 (en) 2012-08-14
ES2260059T3 (en) 2006-11-01
JP2006314328A (en) 2006-11-24
US20080261228A1 (en) 2008-10-23
US20100129824A1 (en) 2010-05-27
US20120315634A1 (en) 2012-12-13
US20110212449A1 (en) 2011-09-01
CA2385477A1 (en) 2001-04-05
PT1222266E (en) 2006-07-31
US9909189B2 (en) 2018-03-06
AU7636400A (en) 2001-04-30
JP4550873B2 (en) 2010-09-22
DE60027027T2 (en) 2006-11-30
EP1222266B1 (en) 2006-03-29
EP1222266A2 (en) 2002-07-17
CA2385477C (en) 2009-11-03
US7927806B2 (en) 2011-04-19
DE60027027D1 (en) 2006-05-18
JP2003510075A (en) 2003-03-18
WO2001023550A2 (en) 2001-04-05
US8618276B2 (en) 2013-12-31
ATE321857T1 (en) 2006-04-15
US7368545B1 (en) 2008-05-06
JP4113228B2 (en) 2008-07-09
US20140087384A1 (en) 2014-03-27
JP2008067704A (en) 2008-03-27
US7655408B2 (en) 2010-02-02
US20160208336A1 (en) 2016-07-21
CY1105048T1 (en) 2010-03-03

Similar Documents

Publication Publication Date Title
WO2000028090A3 (en) Diagnostic assay for cancer
WO2001023550A3 (en) Pca3 messenger rna species in benign and malignant prostate tissues
HUP0200093A2 (en) Trpm-2 antisense therapy
WO2001036685A3 (en) Differential gene expression in cancer
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
WO2001031015A3 (en) 36p6d5: secreted tumor antigen
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
WO1999022773A3 (en) Sequences for targeting metastatic cells
WO2001030964A3 (en) Anti-cancer nucleic acid and protein targets
MX9605716A (en) Methods and compositions for treatment of restenosis and cancer using ribozymes.
WO2001072962A3 (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO1999064576A3 (en) Human genes differentially expressed in colon cancer
WO2002012285A3 (en) The tumor suppressor car-1
AU2740100A (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
IL146125A0 (en) Novel quinones as disease therapies
AU6425800A (en) Agents for the diagnosis, prognosis and treatment of malignant diseases
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2000050595A3 (en) Nucleic acid molecules associated with melanoma and thyroid tumors
WO2002012440A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
WO2002057786A3 (en) Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
WO2000056924A3 (en) Genomic sequence of the purh gene and purh-related biallelic markers
EP1574507A3 (en) Furo- and pyrano-naphthoquinones and their use in the treatment of cancer
HK1118861A1 (en) Genes differentially expressed in breast cancer
WO2001055450A3 (en) AMPLIFIED GENES AT 17q23
CA2360419A1 (en) Molecules for the treatment and diagnosis of tumours

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2385477

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 526932

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000965690

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000965690

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000965690

Country of ref document: EP